Prostate cancer ADC acquired from Fortis breaks FibroGen's clinical losing streak

FibroGen had a run of bad luck in its phase 3 trials last year, but phase 1 data posted this week suggest its earlier-stage pipeline still has potential.

A phase 1 study of the anti-CD46 antibody drug conjugate (ADC) FG-3246 in 56 patients with metastatic castration-resistant prostate cancer demonstrated median progression-free survival (PFS) of 8.7 months and a prostate-specific antigen (PSA) decrease of 50% or more in 36% of participants.